



Global Newswire (2026-08-26)

Prenetics' IM8 CEO and CFO Purchase \$1.0 Million of Shares in the Open Market Following Second Quarter Results

*Cumulative Personal Investment by Leadership Since November 2025
Reaches Approximately \$3.75 Million*

NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health company and parent of the AI-native direct-to-consumer wellness brand IM8, co-founded by David Beckham, today announced that Danny Yeung, Chief Executive Officer, and Brian Rosin, Chief Financial Officer, completed open market purchases of the Company's ordinary shares during the period between August 20 and August 25, 2026, within the Company's open trading window following the release of second quarter 2026 financial results.

The two executives acquired \$1.0 million of shares. Combined with approximately \$1.45 million of purchases in November 2025 and approximately \$1.30 million in February 2026, Prenetics leadership has now personally invested approximately \$3.75 million in Company shares since November 2025, and has not sold any shares over that period.

Individual Transaction Details

Danny Yeung, Chief Executive Officer

Purchased 24,681 shares for approximately \$502,000, at an average price of roughly \$20.34 per share, across purchases on August 20 and August 24, 2026. This brings his cumulative personal investment to approximately \$1.75 million since November 2025, following approximately \$502,000 in November 2025 and approximately \$750,000 in February 2026.



Brian Rosin, Chief Financial Officer

Purchased 23,100 shares for approximately \$498,000, at an average price of roughly \$21.54 per share, across purchases on August 24 and August 25, 2026 — his first open market purchase since joining the Company in May 2026.

Purchases Follow Second Quarter Results

On August 18, 2026, Prenetics reported total second quarter revenue of \$46.5 million, up approximately 288% year over year, with IM8 revenue of \$45.0 million, up approximately 359% year over year — the brand's sixth consecutive record quarter. IM8 delivered \$20.9 million of revenue in July, with an annualized revenue run-rate of approximately \$251 million, and the Company recorded its first month of positive consolidated Adjusted Free Cash Flow. Prenetics raised full year 2026 revenue guidance to \$220 million to 230 million and introduced full year 2027 revenue guidance of more than \$400 million.

Management Commentary

Danny Yeung, Chief Executive Officer of Prenetics, stated: *"This is my third open market purchase since November, and the reason has not changed — the business has only gotten stronger. The clearest validation came in July, when General Catalyst's Customer Value Fund committed \$1 billion of growth financing to IM8. We turned consolidated Adjusted Free Cash Flow positive in July, raised our FY 2026 revenue guidance, and introduced FY 2027 revenue guidance of more than \$400 million, with a strong product pipeline behind it. I would encourage everyone to read our highly detailed shareholder letter and investor presentation we published last week. We are still so early in this journey, and I am backing that view with my own money."*

Brian Rosin, Chief Financial Officer, added: *"I have spent my career in consumer health and have seen plenty of good brands, but what drew me to IM8 was a set of special characteristics I had not seen combined anywhere else. Three months inside Prenetics, the detail has only confirmed those traits run deeper than I thought. Capital allocation is the*



core of my job, and I'm applying that same discipline to my own capital and buying in my first available window."

About Prenetics

Prenetics Global Limited (NASDAQ: PRE) is a leading consumer health company on a mission to advance human health and longevity. Its flagship brand, IM8, co-founded with David Beckham, is redefining premium daily nutrition through science-backed formulations — anchored by Daily Ultimate Essentials, a 90-ingredient daily nutrition system that is NSF Certified for Sport and clinically studied. IM8 is the fastest-growing premium supplement brand ever recorded, reaching approximately \$251 million in annualized run-rate revenue within 20 months of launch, shipping to 46 countries, and delivering well over 200,000 servings daily. IM8's ambassador and equity-partner roster includes David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty, and Inter Miami CF. Learn more at prenetics.com and im8health.com.

About IM8

IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature's most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8's flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com. Follow IM8 on Instagram at [@im8health](https://www.instagram.com/im8health) for updates.



Investor Relations Contact

investors@prenetics.com

PRE@mzgroup.us

Angela Cheung

Investor Relations / Corporate Finance

angela.hm.cheung@prenetics.com